Roche To Commence Phase III Trials With Innovative Treatment Designed To Lower Cardiovascular Risk In Diabetes Patients With Recent Heart Attack
Roche announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at the American Diabetes Association meeting in New Orleans. The Phase III program is anticipated to start in the second half of 2009.
Medical Devices
Pages: 1 [2]
Swine Flu Update Issued On Monday 29 June 2009, Wales
with the antiviral oseltamavir (Tamiflu®) and zanamivir (Relenza®). -- Further information on swine flu and Pandemic Flu is available bilingually from http://www.nphs.wales.nhs.uk -- Further information from the Welsh Assembly Government response is available bilingually at http://www.wales.gov.uk Welsh Assembly GovernmentPages: 1 [2]